Full View

YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis

J Wen, L Xue, Y Wei, J Liang, W Jia, T Yong… - Advanced …, 2024 - Wiley Online Library
Abstract N6‐methyladenosine (m6A) modification orchestrates cancer formation and
progression by affecting the tumor microenvironment (TME). For hepatocellular carcinoma …
被引用次数：2 相关文章

YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.

J Wen, L Xue, Y Wei, J Liang, W Jia, T Yong… - Advanced Science …, 2024 - europepmc.org
Abstract N6‐methyladenosine (m 6 A) modification orchestrates cancer formation and
progression by affecting the tumor microenvironment (TME). For hepatocellular carcinoma …
[HTML] nih.gov

[HTML][HTML] YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis

J Wen, L Xue, Y Wei, J Liang, W Jia, T Yong… - Advanced …, 2024 - ncbi.nlm.nih.gov
Abstract N6‐methyladenosine (m 6 A) modification orchestrates cancer formation and
progression by affecting the tumor microenvironment (TME). For hepatocellular carcinoma …

YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis

J Wen, L Xue, Y Wei, J Liang, W Jia… - Advanced science …, 2024 - pubmed.ncbi.nlm.nih.gov
N6-methyladenosine (m 6 A) modification orchestrates cancer formation and progression by
affecting the tumor microenvironment (TME). For hepatocellular carcinoma (HCC), immune …

YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.

J Wen, L Xue, Y Wei, J Liang, W Jia, T Yong… - Advanced Science …, 2024 - europepmc.org
N6-methyladenosine (m 6 A) modification orchestrates cancer formation and progression by
affecting the tumor microenvironment (TME). For hepatocellular carcinoma (HCC), immune …